GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (MEX:RMD) » Definitions » Cyclically Adjusted PS Ratio

ResMed (MEX:RMD) Cyclically Adjusted PS Ratio : 8.76 (As of May. 22, 2025)


View and export this data going back to 2019. Start your Free Trial

What is ResMed Cyclically Adjusted PS Ratio?

As of today (2025-05-22), ResMed's current share price is MXN4745.00. ResMed's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN541.56. ResMed's Cyclically Adjusted PS Ratio for today is 8.76.

The historical rank and industry rank for ResMed's Cyclically Adjusted PS Ratio or its related term are showing as below:

MEX:RMD' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 6.12   Med: 9.52   Max: 18.37
Current: 9.82

During the past years, ResMed's highest Cyclically Adjusted PS Ratio was 18.37. The lowest was 6.12. And the median was 9.52.

MEX:RMD's Cyclically Adjusted PS Ratio is ranked worse than
86.69% of 481 companies
in the Medical Devices & Instruments industry
Industry Median: 2.18 vs MEX:RMD: 9.82

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ResMed's adjusted revenue per share data for the three months ended in Mar. 2025 was MXN179.504. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN541.56 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


ResMed Cyclically Adjusted PS Ratio Historical Data

The historical data trend for ResMed's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed Cyclically Adjusted PS Ratio Chart

ResMed Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.65 15.31 11.09 10.40 8.17

ResMed Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.67 8.17 10.18 9.34 8.86

Competitive Comparison of ResMed's Cyclically Adjusted PS Ratio

For the Medical Instruments & Supplies subindustry, ResMed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ResMed's Cyclically Adjusted PS Ratio falls into.


;
;

ResMed Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

ResMed's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=4745.00/541.56
=8.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, ResMed's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=179.504/134.9266*134.9266
=179.504

Current CPI (Mar. 2025) = 134.9266.

ResMed Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 49.744 100.684 66.662
201509 48.890 100.392 65.708
201512 55.266 99.792 74.724
201603 55.321 100.470 74.293
201606 67.700 101.688 89.829
201609 63.338 101.861 83.898
201612 76.956 101.863 101.935
201703 67.837 102.862 88.983
201706 70.505 103.349 92.047
201709 66.235 104.136 85.819
201712 82.088 104.011 106.487
201803 74.651 105.290 95.664
201806 84.942 106.317 107.800
201809 76.399 106.507 96.785
201812 88.566 105.998 112.737
201903 89.002 107.251 111.969
201906 93.452 108.070 116.676
201909 92.664 108.329 115.415
201912 95.373 108.420 118.690
202003 123.848 108.902 153.445
202006 121.674 108.767 150.937
202009 113.697 109.815 139.696
202012 108.685 109.897 133.439
202103 107.993 111.754 130.385
202106 118.943 114.631 140.002
202109 126.572 115.734 147.562
202112 124.847 117.630 143.205
202203 117.126 121.301 130.283
202206 125.129 125.017 135.048
202209 129.917 125.227 139.980
202212 136.724 125.222 147.320
202303 136.586 127.348 144.715
202306 130.310 128.729 136.584
202309 130.190 129.860 135.270
202312 133.774 129.419 139.467
202403 134.726 131.776 137.947
202406 151.871 132.554 154.590
202409 163.354 133.029 165.684
202412 181.304 133.157 183.713
202503 179.504 134.927 179.504

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ResMed  (MEX:RMD) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


ResMed Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of ResMed's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ResMed Business Description

Address
9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.